Dexamethasone in Hospitalized Patients with Covid-19

RECOVERY

In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower

28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory Support.

https://s3-us-west-2.amazonaws.com/secure.notion-static.com/f8911586-9a12-45b0-aee4-e70228c50927/Untitled.png

Remdesivir for the Treatment of Covid-19

ACTT-1

Among patients with Covid-19 hospitalized with lower respiratory tract involvement, remdesivir reduced the median time to recovery by approximately four days.

There was no difference in 14-day survival between remdesivir and placebo groups. The report of 28-day mortality is pending.

Solidarity (WHO)

No benefit

Baricitinib

ACTT-2

Remdesivir, Baricitinib Janus kinase (JAK) inhibitor

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.

Hydroxychloroquine (HCQ)

RECOVERY

No benefit